Miser, J.S., et al. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. OncoL5(8):1191-1198, August, 1987.
2.
Antman, K. et al. Phase II trial of Ifosfamide with mesna in previously treated metastatic sarcoma. Ca. Treat. Rep.69:499-504, 1985.
3.
Morgan, L.R. , et al. The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung. Sem. in Oncol. 9(Suppl 1):71-74, 1982.
4.
Brock, N.The oxazaphosphorines. Ca. Treat. Rev. 10(Suppl A): 3-15, 1983.
5.
Colvin, M.The comparative pharmacology of CTX and IFOS. Sem. in OncoL9 (Suppl 1):2-7, 1982.
6.
Brock, N., and Pohl, J.The development of mesna for regional detoxification. Ca. Treat. Rev. 10 (Suppl A):33-43, 1983.
7.
Department of Pediatrics, National Institutes of Health, Personal communication, August 27, 1987.
8.
Hilgard, P., Herdrich, K., and Brade, W.Ifosfamide - Current aspects and perspectives. Ca Treat. Rev . 10 (Suppl A):183-192, 1983.
9.
U.S. Dept. of Health and Human Services. NCI Investigational Drugs: Pharmaceutical Data, 1986.
10.
Indiana University Hospital Department of Pharmacy , Personal communication, December, 1985.
11.
Burkert, H.Clinical overviews of mesna. Ca. Treat. Rev. 10 (Suppl A):175-181, 1983.
12.
Loehrer, P. , et al. Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J. Clin. OncoL3:367-372,1985.
13.
Klein, H., et al. High-dose IFOS and mesna as continuous infusion over 5 days with a phase I/II trial. Ca. Treat. Rev. 10 (Suppl A):167-173, 1983.
14.
Holoye, P., et al. Prophylaxis of IFOS toxicity with oral acetylcysteine. Sem. in Oncol. 10 (Suppl 1):66-71, 1983.
